Hikma Pharmaceuticals Plc Stock Price, News & Analysis

Gedeon Richter and Hikma Pharmaceuticals announced an exclusive licensing agreement for the commercialization of denosumab biosimilars in the US, referencing Prolia and Xgeva. Richter will handle product development and supply, while Hikma will manage FDA registration and US commercialization. The agreement includes an upfront payment and milestone payments totaling a double-digit million USD figure. This collaboration aims to enhance treatment options in the US market for osteoporosis and bone metastasis.

Hikma Pharmaceuticals has announced a donation of 50,000 vials of Naloxone HCl Injection to the Opioid Safety and Naloxone Network (OSNN) Buyers Club, aiding in the critical shortage of this life-saving treatment for opioid overdoses in the US.

The donation originates from Hikma's sterile injectable manufacturing facility in Cherry Hill, NJ, and aligns with the company's Hikma Community Health initiative, focusing on addressing substance use disorder. Hikma aims to enhance access to naloxone amidst an ongoing overdose crisis.

Hikma Pharmaceuticals has announced its agreement to acquire Custopharm Inc. for $375 million, with an additional $50 million contingent upon meeting commercial milestones. This acquisition enhances Hikma's portfolio, adding 13 approved products and bolstering its R&D capabilities through Custopharm's scientific team and laboratory. Custopharm is expected to generate over $80 million in revenue for the full year of 2021. The transaction is pending approval from the US Federal Trade Commission.

Hikma Pharmaceuticals PLC has announced an exclusive US license agreement with FAES Farma S.A. to commercialize Bilastine tablets, an antihistamine for allergic rhinitis and urticaria. Hikma will obtain FDA regulatory approval and handle commercialization upon approval, providing upfront and milestone payments along with royalties to FAES. This partnership builds on an existing collaboration in the Middle East and North Africa, where Hikma is the exclusive licensee for Bilastine in 15 countries, aiming to enhance its presence in the US allergy market.

Bio-Thera Solutions and Hikma Pharmaceuticals have entered a commercialization agreement for BAT2206, a proposed biosimilar to Stelara in the US. Bio-Thera will handle development and manufacturing, while Hikma gains exclusive rights to commercialization. The deal includes a $20 million upfront payment and potential milestones of up to $130 million. BAT2206 is currently in a Phase III clinical trial, focusing on treating autoimmune diseases. This partnership allows Hikma to expand into the biosimilar market in the US, leveraging Bio-Thera's strong technical capabilities.

Hikma Pharmaceuticals PLC announced the US launch of KLOXXADO™ (naloxone HCl) nasal spray 8mg, approved by the FDA in April 2021 for emergency opioid overdose treatment. KLOXXADO™ delivers twice the naloxone per spray compared to Narcan® 4mg, addressing the rising opioid overdose crisis, which has surged nearly 30% due to the COVID-19 pandemic. With approximately 93,000 overdose deaths last year, KLOXXADO™ aims to enhance emergency response efforts. Hikma aims for broad accessibility to this critical treatment tool.

On April 30, 2021, Hikma Pharmaceuticals announced FDA approval for KLOXXADO^TM (naloxone hydrochloride) nasal spray 8mg. This new treatment is designed for emergency use against opioid overdoses, featuring double the naloxone of Narcan^® (4mg). The rising opioid crisis necessitates innovative solutions, as overdose incidents surged, especially during the COVID-19 pandemic. Community surveys indicate a significant demand for higher naloxone doses, with 34% of Narcan reversals utilizing multiple doses. KLOXXADO^TM is expected to hit the market in late 2021.

Melinta Therapeutics and Hikma Pharmaceuticals have signed an exclusive licensing agreement for Vabomere® and Orbactiv® in the MENA region. Vabomere® is for complicated urinary tract infections, while Orbactiv® is used for acute bacterial skin infections. Hikma will manage the registration and commercialization across 18 markets, expanding their existing partnership. This agreement enhances Hikma's hospital anti-infective portfolio, providing more treatment options for healthcare professionals.

Hikma Pharmaceuticals PLC has signed an exclusive license and distribution agreement with AFT Pharmaceuticals for Combogesic^® IV, a non-opioid intravenous pain relief medication. This agreement grants Hikma exclusive rights to market and distribute the product in the US, which is designed for post-operative use. AFT plans to file for FDA approval in the upcoming months. Hikma aims to expand its portfolio in non-opioid pain management, enhancing access to high-quality medicines for patients and healthcare providers in the US.